Literature DB >> 27105722

Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure.

Andrea Necchi1, Andrea Anichini2, Daniele Raggi2, Patrizia Giannatempo2, Domenico Magazzù3, Nicola Nicolai2, Maurizio Colecchia2, Biagio Paolini2, Elisa Coradeschi3, Elena Tassi2, Giulia Grazia2, Roberta Mortarini2, Giuseppina Calareso2, Raffaella De Fato3, Elena Togliardi2, Flavio Crippa2, Roberto Salvioni2, Pinuccia Valagussa3, Alessandro M Gianni2.   

Abstract

Entities:  

Keywords:  Brentuximab vedotin; CD30; Embryonal carcinoma; Salvage therapy; Testicular cancer

Mesh：

Substances：

Year:  2016        PMID： 27105722     DOI： 10.1016/j.clgc.2016.03.020

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  5 in total

1.  Recent developments in the management of germ cell tumors.

Authors:  Pavlos Msaouel; Mehmet A Bilen; Miao Zhang; Matthew Campbell; Jennifer Wang; Shi-Ming Tu
Journal:  Curr Opin Oncol       Date:  2017-05       Impact factor: 3.645

2.  Brentuximab-vedotin maintenance following chemotherapy without irradiation for primary intracranial embryonal carcinoma in down syndrome.

Authors:  Mohammad H Abu Arja; Suzanne E Conley; Violeta Salceda; Fahd Al-Sufiani; Daniel R Boué; Jonathan L Finlay
Journal:  Childs Nerv Syst       Date:  2017-12-13       Impact factor: 1.475

Review 3.  Overcoming Chemotherapy Resistance in Germ Cell Tumors.

Authors:  Zuzana Országhová; Katarina Kalavska; Michal Mego; Michal Chovanec
Journal:  Biomedicines       Date:  2022-04-22

4.  Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.

Authors:  Ryan Ashkar; Darren R Feldman; Nabil Adra; Mohammad Abu Zaid; Samuel A Funt; Sandra K Althouse; Susan M Perkins; Christin I Snow; Kayla M Lazzara; Lina M Sego; David I Quinn; Nasser H Hanna; Lawrence H Einhorn; Costantine Albany
Journal:  Invest New Drugs       Date:  2021-05-24       Impact factor: 3.651

5.  Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.

Authors:  Stefan Schönberger; Cornelius van Beekum; Barbara Götz; Daniel Nettersheim; Hubert Schorle; Dominik T Schneider; Anna Casati; Rogerio B Craveiro; Gabriele Calaminus; Dagmar Dilloo
Journal:  J Cell Mol Med       Date:  2017-09-22       Impact factor: 5.310
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.